Betaville

UNCOOKED ALERT: Viking Therapeutics Inc said to ... - Part 3

Eli Lilly and Company's pursuit of Viking Therapeutics, the US-listed biopharmaceutical company developing obesity drugs, may have stalled.

People following the situation had heard speculation Eli Lilly had been trying to buy Viking for between $40 and $50 a share with a view to announcing a deal last week.

However, Viking decided the indicative price wasn't good enough and opted to announce its drug data, said people following the situation...